Emerging role of mitogen-activated protein kinases in peripheral neuropathies

Journal of the Peripheral Nervous System

Volumn 12, Issue 3, 2007, Pages 175-194

  Cavaletti, Guido ^a   Miloso, Mariarosaria ^a   Nicolini, Gabriella ^a   Scuteri, Arianna ^a   Tredici, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Amyloidosis; Antineoplastic drugs; Diabetes; Experimental allergic neuritis; MAPK; Pathogenesis; Peripheral neuropathies

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BIRD 796; CEP 11004; CEP 1347; DORAMAPIMOD; L 78327; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PLATINUM DERIVATIVE; RO 092210; SCAFFOLD PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CELL DAMAGE; CELL REGENERATION; CENTRAL NERVOUS SYSTEM DISEASE; DIABETIC NEUROPATHY; ENZYME ACTIVATION; FAMILIAL AMYLOID POLYNEUROPATHY; GENE FUNCTION; HUMAN; MOLECULAR BIOLOGY; NERVE CELL; NEURITIS; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SCHWANN CELL;

AMYLOID NEUROPATHIES, FAMILIAL; ANTINEOPLASTIC AGENTS; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NEURITIS, AUTOIMMUNE, EXPERIMENTAL; PERIPHERAL NERVOUS SYSTEM DISEASES; SIGNAL TRANSDUCTION;

EID: 34548623314     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2007.00138.x     Document Type: Review

References (164)

1. Agthong S, Kaewsema A, Tanomsridejchai N, Chentanez V (2006). Activation of MAPK ERK in peripheral nerve after injury. BMC Neurosci 7: 45.
2. Agthong S, Tomlinson DR (2002). Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy. Ann N Y Acad Sci 973: 359 362.
3. Ahn M, Lee Y, Moon C, Jin JK, Matsumoto Y, Koh CS, Kim HM, Shin T (2004). Upregulation of osteopontin in Schwann cells of the sciatic nerves of Lewis rats with experimental autoimmune neuritis. Neurosci Lett 372: 137 141.
4. Ahn M, Moon C, Lee Y, Koh CS, Kohyama K, Tanuma N, Matsumoto Y, Kim HM, Kim SR, Shin T (2004). Activation of extracellular signal-regulated kinases in the sciatic nerves of rats with experimental autoimmune neuritis. Neurosci Lett 372: 57 61.
5. Ahn M, Shin T (2006). Increased phosphorylation of c-Jun NH (2)-terminal protein kinase in the sciatic nerves of Lewis rats with experimental autoimmune neuritis. J Vet Sci 7: 13 17.
6. Averill S, Delcroix JD, Michael GJ, Tomlinson DR, Fernyhough P, Priestley JV (2001). Nerve growth factor modulates the activation status and fast axonal transport of ERK 1/2 in adult nociceptive neurones. Mol Cell Neurosci 18: 183 196.
7. Barr RK, Bogoyevitch MA (2001). The c-Jun N-terminal protein kinase family of mitogen-activated protein kinases (JNK MAPKs). Int J Biochem Cell Biol 33: 1047 1063.
8. Berti-Mattera LN, Harwalkar S, Hughes B, Wilkins PL, Almhanna K (2001). Proliferative and morphological effects of endothelins in Schwann cells: roles of p38 mitogen-activated protein kinase and Ca(2+)-independent phospholipase A2. J Neurochem 79: 1136 1148.
9. Bhalla US, Iyengar R (1999). Emergent properties of networks of biological signaling pathways. Science 283: 381 387.
10. Bloch J, Fine EG, Bouche N, Zurn AD, Aebischer P (2001). Nerve growth factor- and neurotrophin-3-releasing guidance channels promote regeneration of the transected rat dorsal root. Exp Neurol 172: 425 432.
11. Bogoyevitch MA (2005). Therapeutic promise of JNK ATP-noncompetitive inhibitors. Trends Mol Med 11: 232 239.
12. Bogoyevitch MA, Court NW (2004). Counting on mitogen-activated protein kinases-ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 16: 1345 1354.
13. Bogoyevitch MA, Kobe B (2006). Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. Microbiol Mol Biol Rev 70: 1061 1095.
14. Borasio GD, Horstmann S, Anneser JM, Neff NT, Glicksman MA (1998). CEP-1347/KT7515, a JNK pathway inhibitor, supports the in vitro survival of chick embryonic neurons. Neuroreport 9: 1435 1439.
15. Brismar T, Sima AA, Greene DA (1987). Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 21: 504 507.
16. Cameron SJ, Malik S, Akaike M, Lerner-Marmarosh N, Yan C, Lee JD, Abe J, Yang J (2003). Regulation of epidermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase1/ERK5 but not ERK1/2 kinase activation. J Biol Chem 278: 18682 18688.
17. Campana WM, Darin SJ, O'Brien JS (1999). Phosphatidylinositol 3-kinase and Akt protein kinase mediate IGF-I- and prosaptide-induced survival in Schwann cells. J Neurosci Res 57: 332 341.
18. Cavaletti G, Marmiroli P (2004). Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf 3: 535 546.
19. Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, Minoia C, Ronchi A, Bayssas M, Etienne GG (2001). Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 37: 2457 2463.
20. Cavaletti G, Petruccioli MG, Marmiroli P, Rigolio R, Galbiati S, Zoia C, Ferrarese C, Tagliabue E, Dolci C, Bayssas M, Griffon Etienne G, Tredici G (2002). Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat. Anticancer Res 22: 4199 4204.
21. Cavanaugh JE (2004). Role of extracellular signal regulated kinase 5 in neuronal survival. Eur J Biochem 271: 2056 2059.
22. Chang L, Karin M (2001). Mammalian MAP kinase signalling cascades. Nature 410: 37 40.
23. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu B, Wright A, Vanderbilt C, Cobb MH (2001). MAP kinases. Chem Rev 101: 2449 2476.
24. Cheng HL, Steinway ML, Xin X, Feldman EL (2001). Insulin-like growth factor-I and Bcl-X(L) inhibit c-jun N-terminal kinase activation and rescue Schwann cells from apoptosis. J Neurochem 76: 935 943.
25. Chierzi S, Ratto GM, Verma P, Fawcett JW (2005). The ability of axons to regenerate their growth cones depends on axonal type and age, and is regulated by calcium, cAMP and ERK. Eur J Neurosci 21: 2051 2062.
26. Conti G, Baron PL, Scarpini E, Vedeler C, Rostami A, Pleasure D, Scarlato G (1995). Low-affinity nerve growth factor receptor expression in sciatic nerve during P2-peptide induced experimental allergic neuritis. Neurosci Lett 199: 135 138.
27. Conti G, Scarpini E, Rostami A, Livraghi S, Baron PL, Pleasure D, Scarlato G (1998). Schwann cell undergoes apoptosis during experimental allergic neuritis (EAN). J Neurol Sci 161: 29 35.
28. Conti AM, Brimijoin S, Miller LJ, Windebank AJ (2004). Suppression of neurite outgrowth by high-dose nerve growth factor is independent of functional p75NTR receptors. Neurobiol Dis 15: 106 114.
29. Coulombe P, Meloche S (2007). Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim Biophys Acta 1773: 1376 1387.
30. Dard N, Peter M (2006). Scaffold proteins in MAP kinase signaling: more than simple passive activating platforms. Bioessays 28: 146 156.
31. Daulhac L, Mallet C, Courteix C, Etienne M, Duroux E, Privat AM, Eschalier A, Fialip J (2006). Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol 70: 1246 1254.
32. David S, Hila S, Fosbrink M, Rus H, Koski CL (2006). JNK1 activation mediates C5b-9-induced P0 mRNA instability and P0 gene expression in Schwann cells. J Peripher Nerv Syst 11: 77 87.
33. Dodge ME, Rahimtula M, Mearow KM (2002). Factors contributing to neurotrophin-independent survival of adult sensory neurons. Brain Res 953: 144 156.
34. Dolcet X, Soler RM, Gould TW, Egea J, Oppenheim RW, Comella JX (2001). Cytokines promote motoneuron survival through the Janus kinase-dependent activation of the phosphatidylinositol 3-kinase pathway. Mol Cell Neurosci 18: 619 631.
35. Donzelli E, Carfi M, Miloso M, Strada A, Galbiati S, Bayssas M, Griffon-Etienne G, Cavaletti G, Petruccioli MG, Tredici G (2004). Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol 67: 65 73.
36. Ebisuya M, Kondoh K, Nishida E (2005). The duration, magnitude and compartmentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity. J Cell Sci 118: 2997 3002.
37. English JM, Cobb MH (2002). Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23: 40 45.
38. Falls DL (2003). Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284: 14 30.
39. Farinas I (1999). Neurotrophin actions during the development of the peripheral nervous system. Microsc Res Tech 45: 233 242.
40. Farooq A, Zhou MM (2004). Structure and regulation of MAPK phosphatases. Cell Signal 16: 769 779.
41. Feldman EL, Russell JW, Sullivan KA, Golovoy D (1999). New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol 12: 553 563.
42. Fernyhough P, Gallagher A, Averill SA, Priestley JV, Hounsom L, Patel J, Tomlinson DR (1999). Aberrant neurofilament phosphorylation in sensory neurons of rats with diabetic neuropathy. Diabetes 48: 881 889.
43. Fragoso G, Robertson J, Athlan E, Tam E, Almazan G, Mushynski WE (2003). Inhibition of p38 mitogen-activated protein kinase interferes with cell shape changes and gene expression associated with Schwann cell myelination. Exp Neurol 183: 34 46.
44. Gill JS, Windebank AJ (1998). Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101: 2842 2850.
45. Gold R, Hartung HP, Toyka KV (2000). Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today 6: 88 91.
46. Goold RG, Gordon-Weeks PR (2005). The MAP kinase pathway is upstream of the activation of GSK3beta that enables it to phosphorylate MAP1B and contributes to the stimulation of axon growth. Mol Cell Neurosci 28: 524 534.
47. Gozdz A, Habas A, Jaworski J, Zielinska M, Albrecht J, Chlystun M, Jalili A, Hetman M (2003). Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin. J Biol Chem 278: 43663 43671.
48. Hancock CN, Macias AT, Mackerell AD Jr., Shapiro P (2006). Mitogen activated protein (MAP) kinases: development of ATP and non-ATP dependent inhibitors. Med Chem 2: 213 222.
49. Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC (2004). The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. Embo J 23: 3061 3071.
50. Hayashi M, Tapping RI, Chao TH, Lo JF, King CC, Yang Y, Lee JD (2001). BMK1 mediates growth factor-induced cell proliferation through direct cellular activation of serum and glucocorticoid-inducible kinase. J Biol Chem 276: 8631 8634.
51. Herdegen T, Claret FX, Kallunki T, Martin-Villalba A, Winter C, Hunter T, Karin M (1998). Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. J Neurosci 18: 5124 5135.
52. Ho EC, Lam KS, Chen YS, Yip JC, Arvindakshan M, Yamagishi S, Yagihashi S, Oates PJ, Ellery CA, Chung SS, Chung SK (2006). Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity, increased c-Jun NH2-terminal kinase activation, depletion of reduced glutathione, increased superoxide accumulation, and DNA damage. Diabetes 55: 1946 1953.
53. Hornberg JJ, Bruggeman FJ, Binder B, Geest CR, de Vaate AJ, Lankelma J, Heinrich R, Westerhoff HV (2005). Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control. FEBS J 272: 244 258.
54. Horstmann S, Kahle PJ, Borasio GD (1998). Inhibitors of p38 mitogen-activated protein kinase promote neuronal survival in vitro. J Neurosci Res 52: 483 490.
55. Ishihara K, Tsutsumi K, Kawane S, Nakajima M, Kasaoka T (2003). The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site. FEBS Lett 550: 107 113.
56. Janssens V, Goris J (2001). Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 353: 417 439.
57. Jessen KR, Mirsky R (2005). The origin and development of glial cells in peripheral nerves. Nat Rev Neurosci 6: 671 682.
58. Johnson EO, Zoubos AB, Soucacos PN (2005). Regeneration and repair of peripheral nerves. Injury 36: S24 S29.
59. Jones DM, Tucker BA, Rahimtula M, Mearow KM (2003). The synergistic effects of NGF and IGF-1 on neurite growth in adult sensory neurons: convergence on the PI 3-kinase signaling pathway. J Neurochem 86: 1116 1128.
60. Kang YJ, Seit-Nebi A, Davis RJ, Han J (2006). Multiple activation mechanisms of p38alpha mitogen-activated protein kinase. J Biol Chem 281: 26225 26234.
61. Kaplan DR, Miller FD (2000). Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10: 381 391.
62. Karlsson M, Mandl M, Keyse SM (2006). Spatio-temporal regulation of mitogen-activated protein kinase (MAPK) signalling by protein phosphatases. Biochem Soc Trans 34: 842 845.
63. Kelemen BR, Hsiao K, Goueli SA (2002). Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 277: 8741 8748.
64. Kenney AM, Kocsis JD (1998). Peripheral axotomy induces long-term c-Jun amino-terminal kinase-1 activation and activator protein-1 binding activity by c-Jun and junD in adult rat dorsal root ganglia in vivo. J Neurosci 18: 1318 1328.
65. Klesse LJ, Parada LF (1998). p21 ras and phosphatidylinositol-3 kinase are required for survival of wild-type and NF1 mutant sensory neurons. J Neurosci 18: 10420 10428.
66. Klesse LJ, Parada LF (1999). Trks: signal transduction and intracellular pathways. Microsc Res Tech 45: 210 216.
67. Klinz FJ, Wolff P, Heumann R (1996). Nerve growth factor-stimulated mitogen-activated protein kinase activity is not necessary for neurite outgrowth of chick dorsal root ganglion sensory and sympathetic neurons. J Neurosci Res 46: 720 726.
68. Kolch W (2005). Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6: 827 837.
69. Kondoh K, Nishida E (2007). Regulation of MAP kinases by MAP kinase phosphatases. Biochim Biophys Acta 1773: 1227 1237.
70. Kondoh K, Torii S, Nishida E (2005). Control of MAP kinase signaling to the nucleus. Chromosoma 114: 86 91.
71. Kondoh K, Terasawa K, Morimoto H, Nishida E (2006). Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms. Mol Cell Biol 26: 1679 1690.
72. Koyama T, Mikami T, Koyama T, Imakiire A, Yamamoto K, Toyota H, Mizuguchi J (2006). Apoptosis induced by chemotherapeutic agents involves c-Jun N-terminal kinase activation in sarcoma cell lines. J Orthop Res 24: 1153 1162.
73. Lee MR, Dominguez C (2005). MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 12: 2979 2994.
74. Lee Y, Shin T (2002). Expression of constitutive endothelial and inducible nitric oxide synthase in the sciatic nerve of Lewis rats with experimental autoimmune neuritis. J Neuroimmunol 126: 78 85.
75. Lewis TS, Shapiro PS, Ahn NG (1998). Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49 139.
76. Lindwall C, Kanje M (2005). Retrograde axonal transport of JNK signaling molecules influence injury induced nuclear changes in p-c-Jun and ATF3 in adult rat sensory neurons. Mol Cell Neurosci 29: 269 282.
77. Lindwall C, Kanje M (2005). The role of p-c-Jun in survival and outgrowth of developing sensory neurons. Neuroreport 16: 1655 1659.
78. Lloyd AC (2006). Distinct functions for ERKs? J Biol 5: 13.
79. Makkinje A, Quinn DA, Chen A, Cadilla CL, Force T, Bonventre JV, Kyriakis JM (2000). Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 275: 17838 17847.
80. Marshall CJ (1995). Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179 185.
81. Martin H, Flandez M, Nombela C, Molina M (2005). Protein phosphatases in MAPK signalling: we keep learning from yeast. Mol Microbiol 58: 6 16.
82. Maurel P, Salzer JL (2000). Axonal regulation of Schwann cell proliferation and survival and the initial events of myelination requires PI 3-kinase activity. J Neurosci 20: 4635 4645.
83. McHugh JM, McHugh WB (2004). Diabetes and peripheral sensory neurons: what we don't know and how it can hurt us. AACN Clin Issues 15: 136 149.
84. Meier C, Parmantier E, Brennan A, Mirsky R, Jessen KR (1999). Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci 19: 3847 3859.
85. Meintanis S, Thomaidou D, Jessen KR, Mirsky R, Matsas R (2001). The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway. Glia 34: 39 51.
86. Melov S (2000). Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging. Ann N Y Acad Sci 908: 219 225.
87. Middlemas A, Delcroix JD, Sayers NM, Tomlinson DR, Fernyhough P (2003). Enhanced activation of axonally transported stress-activated protein kinases in peripheral nerve in diabetic neuropathy is prevented by neurotrophin-3. Brain 126: 1671 1682.
88. Middlemas AB, Agthong S, Tomlinson DR (2006). Phosphorylation of c-Jun N-terminal kinase (JNK) in sensory neurones of diabetic rats, with possible effects on nerve conduction and neuropathic pain: prevention with an aldose reductase inhibitor. Diabetologia 49: 580 587.
89. Miloso M, Villa D, Crimi M, Galbiati S, Donzelli E, Nicolini G, Tredici G (2004). Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent. J Neurosci Res 75: 241 252.
90. Monje PV, Bartlett Bunge M, Wood PM (2006). Cyclic AMP synergistically enhances neuregulin-dependent ERK and Akt activation and cell cycle progression in Schwann cells. Glia 53: 649 659.
91. Monteiro FA, Sousa MM, Cardoso I, do Amaral JB, Guimaraes A, Saraiva MJ (2006). Activation of ERK1/2 MAP kinases in familial amyloidotic polyneuropathy. J Neurochem 97: 151 161.
92. Moon C, Ahn M, Kim H, Lee Y, Koh CS, Matsumoto Y, Shin T (2005). Activation of p38 mitogen-activated protein kinase in the early and peak phases of autoimmune neuritis in rat sciatic nerves. Brain Res 1040: 208 213.
93. Moore SA, Peterson RG, Felten DL, Cartwright TR, O'Connor BL (1980). Reduced sensory and motor conduction velocity in 25-week-old diabetic [C57BL/Ks (db/db)] mice. Exp Neurol 70: 548 555.
94. Morrison DK, Davis RJ (2003). Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 19: 91 118.
95. Murashov AK, Ul Haq I, Hill C, Park E, Smith M, Wang X, Wang X, Goldberg DJ, Wolgemuth DJ (2001). Crosstalk between p38, Hsp25 and Akt in spinal motor neurons after sciatic nerve injury. Brain Res Mol Brain Res 93: 199 208.
96. Myers RR, Sekiguchi Y, Kikuchi S, Scott B, Medicherla S, Protter A, Campana WM (2003). Inhibition of p38 MAP kinase activity enhances axonal regeneration. Exp Neurol 184: 606 614.
97. Nave KA, Salzer JL (2006). Axonal regulation of myelination by neuregulin 1. Curr Opin Neurobiol 16: 492 500.
98. Newbern J, Taylor A, Robinson M, Li L, Milligan CE (2005). Decreases in phosphoinositide-3-kinase/Akt and extracellular signal-regulated kinase 1/2 signaling activate components of spinal motoneuron death. J Neurochem 94: 1652 1665.
99. Nicolini G, Rigolio R, Scuteri A, Miloso M, Saccomanno D, Cavaletti G, Tredici G (2003). Effect of trans-resveratrol on signal transduction pathways involved in paclitaxel-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurochem Int 42: 419 429.
100. Nishimoto S, Nishida E (2006). MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 7: 782 786.
101. Obata T, Brown GE, Yaffe MB (2000). MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 28: N67 N677.
102. Obata K, Yamanaka H, Dai Y, Tachibana T, Fukuoka T, Tokunaga A, Yoshikawa H, Noguchi K (2003). Differential activation of extracellular signal-regulated protein kinase in primary afferent neurons regulates brain-derived neurotrophic factor expression after peripheral inflammation and nerve injury. J Neurosci 23: 4117 4126.
103. Obata K, Yamanaka H, Dai Y, Mizushima T, Fukuoka T, Tokunaga A, Noguchi K (2004). Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur J Neurosci 20: 2881 2895.
104. Ocean AJ, Vahdat LT (2004). Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12: 619 625.
105. Ogata T, Iijima S, Hoshikawa S, Miura T, Yamamoto S, Oda H, Nakamura K, Tanaka S (2004). Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J Neurosci 24: 6724 6732.
106. Ono K, Han J (2000). The p38 signal transduction pathway: activation and function. Cell Signal 12: 1 13.
107. Parkinson DB, Bhaskaran A, Droggiti A, Dickinson S, D'Antonio M, Mirsky R, Jessen KR (2004). Krox-20 inhibits Jun-NH2-terminal kinase/c-Jun to control Schwann cell proliferation and death. J Cell Biol 164: 385 394.
108. Parkinson DB, Langner K, Namini SS, Jessen KR, Mirsky R (2002). beta-Neuregulin and autocrine mediated survival of Schwann cells requires activity of Ets family transcription factors. Mol Cell Neurosci 20: 154 167.
109. Pasterkamp RJ, Peschon JJ, Spriggs MK, Kolodkin AL (2003). Semaphorin 7A promotes axon outgrowth through integrins and MAPKs. Nature 424: 398 405.
110. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH (2001). Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153 183.
111. Peltier AC, Russell JW (2002). Recent advances in drug-induced neuropathies. Curr Opin Neurol 15: 633 638.
112. Petratos S, Butzkueven H, Shipham K, Cooper H, Bucci T, Reid K, Lopes E, Emery B, Cheema SS, Kilpatrick TJ (2003). Schwann cell apoptosis in the postnatal axotomized sciatic nerve is mediated via NGF through the low-affinity neurotrophin receptor. J Neuropathol Exp Neurol 62: 398 411.
113. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G (2003). Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 9: 5756 5767.
114. Pouyssegur J, Volmat V, Lenormand P (2002). Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem Pharmacol 64: 755 763.
115. Price SA, Hounsom L, Purves-Tyson TD, Fernyhough P, Tomlinson DR (2003). Activation of JNK in sensory neurons protects against sensory neuron cell death in diabetes and on exposure to glucose/oxidative stress in vitro. Ann N Y Acad Sci 1010: 95 99.
116. Price SA, Agthong S, Middlemas AB, Tomlinson DR (2004). Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 53: 1851 1856.
117. Price SA, Gardiner NJ, Duran-Jimenez B, Zeef LA, Obrosova IG, Tomlinson DR (2006). Thioredoxin interacting protein is increased in sensory neurons in experimental diabetes. Brain Res 1116: 206 214.
118. Purves T, Middlemas A, Agthong S, Jude EB, Boulton AJ, Fernyhough P, Tomlinson DR (2001). A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 15: 2508 2514.
119. Purves TD, Tomlinson DR (2002). Are mitogen-activated protein kinases glucose transducers for diabetic neuropathies? Int Rev Neurobiol 50: 83 114.
120. Quasthoff S, Hartung HP (2002). Chemotherapy-induced peripheral neuropathy. J Neurol 249: 9 17.
121. Rosen LB, Ginty DD, Weber MJ, Greenberg ME (1994). Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron 12: 1207 1221.
122. Roux PP, Blenis J (2004). ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68: 320 344.
123. Salvarezza SB, Lopez HS, Masco DH (2003). The same cellular signaling pathways mediate survival in sensory neurons that switch their trophic requirements during development. J Neurochem 85: 1347 1358.
124. Schmidt RE, Dorsey D, Parvin CA, Beaudet LN, Plurad SB, Roth KA (1997). Dystrophic axonal swellings develop as a function of age and diabetes in human dorsal root ganglia. J Neuropathol Exp Neurol 56: 1028 1043.
125. Scuteri A, Nicolini G, Miloso M, Bossi M, Cavaletti G, Windebank AJ, Tredici G (2006). Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res 26: 1065 1070.
126. Sheu JY, Kulhanek DJ, Eckenstein FP (2000). Differential patterns of ERK and STAT3 phosphorylation after sciatic nerve transection in the rat. Exp Neurol 166: 392 402.
127. Sima AA, Brismar T (1985). Reversible diabetic nerve dysfunction: structural correlates to electrophysiological abnormalities. Ann Neurol 18: 21 29.
128. Sima AA, Sugimoto K (1999). Experimental diabetic neuropathy: an update. Diabetologia 42: 773 788.
129. Sima AA, Zhang W, Xu G, Sugimoto K, Guberski D, Yorek MA (2000). A comparison of diabetic polyneuropathy in type II diabetic BBZDR/Wor rats and in type I diabetic BB/Wor rats. Diabetologia 43: 786 793.
130. Sjogreen B, Wiklund P, Ekstrom PA (2000). Mitogen activated protein kinase inhibition by PD98059 blocks nerve growth factor stimulated axonal outgrowth from adult mouse dorsal root ganglia in vitro. Neuroscience 100: 407 416.
131. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ (2001). Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159: 1993 2000.
132. Stevens B (2006). Cross-talk between growth factor and purinergic signalling regulates Schwann cell proliferation. Novartis Found Symp 276: 162 175 discussion 175 180, 233 237, 275 281.
133. Stillman M, Cata JP (2006). Management of chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 10: 279 287.
134. Sugimoto K, Murakawa Y, Zhang W, Xu G, Sima AA (2000). Insulin receptor in rat peripheral nerve: its localization and alternatively spliced isoforms. Diabetes Metab Res Rev 16: 354 363.
135. Sung YJ, Wu F, Schacher S, Ambron RT (2006). Synaptogenesis regulates axotomy-induced activation of c-Jun-activator protein-1 transcription. J Neurosci 26: 6439 6449.
136. Takahashi K, Yi S, Kimura Y, Araki S (1991). Familial amyloidotic polyneuropathy type 1 in Kumamoto, Japan: a clinicopathologic, histochemical, immunohistochemical, and ultrastructural study. Hum Pathol 22: 519 527.
137. Tanoue T, Nishida E (2002). Docking interactions in the mitogen-activated protein kinase cascades. Pharmacol Ther 93: 193 202.
138. Tanoue T, Nishida E (2003). Molecular recognitions in the MAP kinase cascades. Cell Signal 15: 455 462.
139. Tanoue T, Maeda R, Adachi M, Nishida E (2001). Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions. Embo J 20: 466 479.
140. Theodosiou A, Ashworth A (2002). MAP kinase phosphatases. Genome Biol 3: REVIEWS3009: 1 10.
141. Tibbles LA, Woodgett JR (1999). The stress-activated protein kinase pathways. Cell Mol Life Sci 55: 1230 1254.
142. Tomlinson DR (1999). Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 42: 1271 1281.
143. Toyoshima F, Moriguchi T, Nishida E (1997). Fas induces cytoplasmic apoptotic responses and activation of the MKK7-JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases. J Cell Biol 139: 1005 1015.
144. Tredici G, Braga M, Nicolini G, Miloso M, Marmiroli P, Schenone A, Nobbio L, Frattola L, Cavaletti G (1999). Effect of recombinant human nerve growth factor on cisplatin neurotoxicity in rats. Exp Neurol 159: 551 558.
145. Vantaggiato C, Formentini I, Bondanza A, Bonini C, Naldini L, Brambilla R (2006). ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. J Biol 5: 14.
146. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ (2003). Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63: 1549 1563.
147. Volmat V, Pouyssegur J (2001). Spatiotemporal regulation of the p42/p44 MAPK pathway. Biol Cell 93: 71 79.
148. Waetzig V, Herdegen T (2005). Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol Sci 26: 455 461.
149. Walsh GS, Orike N, Kaplan DR, Miller FD (2004). The invulnerability of adult neurons: a critical role for p73. J Neurosci 24: 9638 9647.
150. Wang X, Tournier C (2006). Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 18: 753 760.
151. Wang X, Destrument A, Tournier C (2007). Physiological roles of MKK4 and MKK7: insights from animal models. Biochim Biophys Acta 1773: 1349 1357.
152. Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, Segal RA (2001). Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat Neurosci 4: 981 988.
153. Weishaupt A, Bruck W, Hartung T, Toyka KV, Gold R (2001). Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-alpha. Neurosci Lett 306: 77 80.
154. Wellbrock C, Karasarides M, Marais R (2004). The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5: 875 885.
155. Wiklund P, Ekstrom PA, Edstrom A (2002). Mitogen-activated protein kinase inhibition reveals differences in signalling pathways activated by neurotrophin-3 and other growth-stimulating conditions of adult mouse dorsal root ganglia neurons. J Neurosci Res 67: 62 68.
156. Yagihashi S, Wada R, Kamijo M, Nagai K (1993). Peripheral neuropathy in the WBN/Kob rat with chronic pancreatitis and spontaneous diabetes. Lab Invest 68: 296 307.
157. Yamauchi J, Chan JR, Shooter EM (2003). Neurotrophin 3 activation of TrkC induces Schwann cell migration through the c-Jun N-terminal kinase pathway. Proc Natl Acad Sci U S A 100: 14421 14426.
158. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinsky D, Stern D (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269: 9889 9897.
159. Yoon S, Seger R (2006). The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24: 21 44.
160. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, Stork PJ (1998). Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392: 622 626.
161. Zhang Q, Muller M, Chen CH, Zeng L, Farooq A, Zhou MM (2005). New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding. J Mol Biol 354: 777 788.
162. Zhuang S, Demirs JT, Kochevar IE (2000). p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide. J Biol Chem 275: 25939 25948.
163. Zill H, Bek S, Hofmann T, Huber J, Frank O, Lindenmeier M, Weigle B, Erbersdobler HF, Scheidler S, Busch AE, Faist V (2003). RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 300: 311 315.
164. Zorick TS, Lemke G (1996). Schwann cell differentiation. Curr Opin Cell Biol 8: 870 876.